Table 1.
BRAF mutation and clinicopathological characteristics of papillary thyroid cancer (PTC)
| Parameters | Number (%) | BRAF mutation (+) | BRAF mutation (-) | χ2 | P value |
|---|---|---|---|---|---|
| Cases (n) | 59 | 36 | |||
| Age (years) | 0.043 | 0.835 | |||
| < 45 | 37 (38.9%) | 23 (39.0%) | 14 (38.9%) | ||
| ≥ 45 | 58 (61.1%) | 36 (61.0%) | 22 (61.1%) | ||
| Gender | 3.356 | 0.067 | |||
| Male | 29 (30.5%) | 22 (37.3%) | 7 (19.4%) | ||
| Female | 66 (69.5%) | 37 (62.7%) | 29 (80.6%) | ||
| Type of surgery | 1.141 | 0.565 | |||
| Right resection | 29 (30.5%) | 20 (33.9%) | 9 (25.0%) | ||
| Left resection | 34 (35.8%) | 19 (32.2%) | 15 (41.7%) | ||
| Total resection | 32 (33.7%) | 20 (33.9%) | 12 (33.3%) | ||
| Tumor size (mm) | 0.431 | 0.512 | |||
| < 10 | 54 (56.8%) | 32 (54.2%) | 22 (61.1%) | ||
| ≥ 10 | 41 (43.2%) | 27 (45.8%) | 14 (38.9%) | ||
| Tumor focus | 0.206 | 0.650 | |||
| Unifocal | 66 (69.5%) | 40 (67.8%) | 26 (72.2%) | ||
| Multifocal | 29 (30.5%) | 19 (32.2%) | 10 (27.8%) | ||
| Lymph node metastasis | 2.154 | 0.142 | |||
| Yes | 38 (40.0%) | 27 (45.8%) | 11 (30.6%) | ||
| No | 57 (60.0%) | 32 (54.2%) | 25 (69.4%) | ||
| Pathological TNM classification | |||||
| T stage | 0.127 | 0.721# | |||
| T1 | 87 (91.6%) | 54 (91.5%) | 33 (91.7%) | ||
| T2 | 6 (6.3%) | 3 (5.1%) | 3 (8.3%) | ||
| T3 | 2 (2.1%) | 2 (3.4%) | 0 (0.0%) | ||
| N stage | 2.263 | 0.322# | |||
| N0 | 61 (64.2%) | 35 (59.3%) | 26 (72.2%) | ||
| N1a | 20 (21.1%) | 13 (22.0%) | 7 (19.5%) | ||
| N1b | 14 (14.7%) | 11 (18.7%) | 3 (8.3%) | ||
| TNM stage | 4.252 | 0.039# | |||
| I | 77 (81.1%) | 44 (74.5%) | 33 (91.7%) | ||
| II | 1 (1.1%) | 1 (1.7%) | 0 (0.0%) | ||
| III | 10 (10.5%) | 7 (11.9%) | 3 (8.3%) | ||
| IVa | 7 (7.3%) | 7 (11.9%) | 0 (0.0%) | ||
| White blood cell (W) | 0.118 | 0.732 | |||
| < 5.82 | 47 (49.5%) | 30 (50.9%) | 17 (47.2%) | ||
| ≥ 5.82 | 48 (50.5%) | 29 (49.1%) | 19 (52.8%) | ||
| Hemoglobin (Hb) | 2.795 | 0.095 | |||
| < 137 | 45 (47.4%) | 24 (40.7%) | 21 (58.3%) | ||
| ≥ 137 | 50 (52.6%) | 35 (59.3%) | 15 (41.7%) | ||
| Neutrophils (N) | 0.199 | 0.656 | |||
| < 3.30 | 45 (47.4%) | 29 (49.1%) | 16 (44.4%) | ||
| ≥ 3.30 | 50 (52.6%) | 30 (50.9%) | 20 (55.6%) | ||
| Monocyte (M) | 5.298 | 0.021 | |||
| < 0.30 | 26 (27.4%) | 21 (35.6%) | 5 (13.9%) | ||
| ≥ 0.30 | 69 (72.6%) | 38 (64.4%) | 31 (86.1%) | ||
| Platelet (P) | 2.598 | 0.107 | |||
| < 221 | 47 (49.5%) | 33 (55.9%) | 14 (38.9%) | ||
| ≥ 221 | 48 (50.5%) | 26 (44.1%) | 22 (61.1%) | ||
| Lymphocyte (L) | 1.286 | 0.257 | |||
| < 1.90 | 44 (46.3%) | 30 (50.9%) | 14 (38.9%) | ||
| ≥ 1.90 | 51 (53.7%) | 29 (49.1%) | 22 (61.1%) | ||
| SIRI | 4.004 | 0.045 | |||
| < 0.43 | 33 (34.7%) | 25 (42.4%) | 8 (22.2%) | ||
| ≥ 0.43 | 62 (65.3%) | 34 (57.6%) | 28 (77.8%) | ||
| Ki-67 | 0.621 | 0.431 | |||
| Positive | 64 (67.4%) | 38 (64.4%) | 26 (72.2%) | ||
| Negative | 31 (32.6%) | 21 (35.6%) | 10 (27.8%) | ||
| P53 | 0.104 | 0.745 | |||
| Positive | 35 (36.8%) | 21 (35.6%) | 14 (38.9%) | ||
| Negative | 60 (63.2%) | 38 (64.4%) | 22 (61.1%) | ||
| CK19 | 0.696 | 0.404 | |||
| Positive | 85 (89.5%) | 54 (91.5%) | 31 (86.1%) | ||
| Negative | 10 (10.5%) | 5 (8.5%) | 5 (13.9%) | ||
| Galectin-3 | 6.283 | 0.012# | |||
| Positive | 82 (86.3%) | 55 (93.2%) | 27 (75.0%) | ||
| Negative | 13 (13.7%) | 4 (6.8%) | 9 (25.0%) | ||
| CD56 | 0.402 | 0.526 | |||
| Positive | 23 (24.2%) | 13 (22.0%) | 10 (27.8%) | ||
| Negative | 72 (75.8%) | 46 (78.0%) | 26 (72.2%) |
#
Fisher exact test.